Vertex Pharmaceuticals Incorporated announced that the FDA approved Symdeko (tezacaftor/ivacaftor and ivacaftor) for treating the underlying cause of cystic fibrosis...
Vertex Pharmaceuticals Incorporated announced the FDA expanded the eligibility for Trikafta (elexacaftor/tezacaftor/ivacaftor and ivacaftor) to include people with cystic fibrosis (CF) ages 12 years and older with certain mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene that are responsive to Trikafta based on in vitro data.
Vertex Pharmaceuticals Incorporated announced the FDA approved Symdeko (tezacaftor/ivacaftor and ivacaftor) for use in children with cystic fibrosis ages 6...
The EU has approved Symveki (tezacaftor 100mg + ivacaftor 150mg) in a combination regimen with Kalydeco (ivacaftor 150mg) to treat...